PURPOSE: To ameliorate the late-onset of severe gastrointestinal toxicity provoked by irinotecan (CPT-11), which may be related to the biliary excretion of CPT-11 and/or its metabolites. METHODS: Effects of probenecid, an inhibitor of MRP2/ABCC2, on the biliary excretion and mucosal intestinal tissue concentration of CPT-11 and its metabolites were examined in rats. CPT-11-induced late-onset gastrointestinal toxicity was also evaluated. RESULTS: Coadministration of probenecid reduced the biliary excretion of CPT-11, an active metabolite (SN-38) and its glucuronide by half with a concomitant increase in their plasma concentration. When the dose of CPT-11, in the presence of probenecid, was set at half that in its absence, the plasma SN-38 concentration was maintained at the same level as the control, whereas the mucosal intestinal tissue concentration of SN-38 was reduced. Under this condition, CPT-11-induced watery diarrhea, changes in intestinal marker enzymes and body weight reduction were much less in the probenecid-treated group, although the degree of bone marrow suppression was almost the same as that in the control. CONCLUSIONS: Coadministration of probenecid with a reduced dose of CPT-11 potently reduces both SN-38 exposure and CPT-11-induced late-onset toxicity in gastrointestinal tissues, possibly by inhibiting the biliary excretion of CPT-11 and/or its metabolites.
PURPOSE: To ameliorate the late-onset of severe gastrointestinal toxicity provoked by irinotecan (CPT-11), which may be related to the biliary excretion of CPT-11 and/or its metabolites. METHODS: Effects of probenecid, an inhibitor of MRP2/ABCC2, on the biliary excretion and mucosal intestinal tissue concentration of CPT-11 and its metabolites were examined in rats. CPT-11-induced late-onset gastrointestinal toxicity was also evaluated. RESULTS: Coadministration of probenecid reduced the biliary excretion of CPT-11, an active metabolite (SN-38) and its glucuronide by half with a concomitant increase in their plasma concentration. When the dose of CPT-11, in the presence of probenecid, was set at half that in its absence, the plasma SN-38 concentration was maintained at the same level as the control, whereas the mucosal intestinal tissue concentration of SN-38 was reduced. Under this condition, CPT-11-induced watery diarrhea, changes in intestinal marker enzymes and body weight reduction were much less in the probenecid-treated group, although the degree of bone marrow suppression was almost the same as that in the control. CONCLUSIONS: Coadministration of probenecid with a reduced dose of CPT-11 potently reduces both SN-38 exposure and CPT-11-induced late-onset toxicity in gastrointestinal tissues, possibly by inhibiting the biliary excretion of CPT-11 and/or its metabolites.
Authors: T P Schaub; J Kartenbeck; J König; H Spring; J Dörsam; G Staehler; S Störkel; W F Thon; D Keppler Journal: J Am Soc Nephrol Date: 1999-06 Impact factor: 10.121
Authors: S Negoro; M Fukuoka; N Masuda; M Takada; Y Kusunoki; K Matsui; N Takifuji; S Kudoh; H Niitani; T Taguchi Journal: J Natl Cancer Inst Date: 1991-08-21 Impact factor: 13.506
Authors: F Lokiec; P Canal; C Gay; E Chatelut; J P Armand; H Roché; R Bugat; E Gonçalvès; A Mathieu-Boué Journal: Cancer Chemother Pharmacol Date: 1995 Impact factor: 3.333
Authors: S Kudoh; M Fukuoka; N Masuda; A Yoshikawa; Y Kusunoki; K Matsui; S Negoro; N Takifuji; K Nakagawa; T Hirashima Journal: Jpn J Cancer Res Date: 1995-04
Authors: Erica L Toth; Hui Li; Anika L Dzierlenga; John D Clarke; Anna Vildhede; Michael Goedken; Nathan J Cherrington Journal: Drug Metab Dispos Date: 2018-08-30 Impact factor: 3.922
Authors: Hongwang Wang; Tej B Shrestha; Matthew T Basel; Raj Kumar Dani; Gwi-Moon Seo; Sivasai Balivada; Marla M Pyle; Heidy Prock; Olga B Koper; Prem S Thapa; David Moore; Ping Li; Viktor Chikan; Deryl L Troyer; Stefan H Bossmann Journal: Beilstein J Nanotechnol Date: 2012-06-13 Impact factor: 3.649